Drug Trial Radar · NCT04609111
ShorT and OPtimal Duration of Dual AntiPlatelet Therapy-3 Study
Last checked: Nov 20, 2026Latest source record: Jun 14, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
6,002
Actual
Start
Jan 29, 2021
Primary completion
Dec 31, 2023
Study completion Dec 31, 2025
Sponsor
- Lead sponsor
- Kyoto University, Graduate School of MedicineAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Oct 30, 2020
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to explore the benefit of the prasugrel monotherapy without aspirin as compared with the 1-month dual therapy with aspirin and prasugrel in terms of reducing bleeding events after percutaneous coronary intervention (PCI) using cobalt-chromium everolimus-eluting stents (CoCr-EES, XienceTM) in patients with high bleeding risk or under the acute coronary syndrome patients.
Conditions
- Acute Coronary Syndrome
Interventions
No aspirinDrug
1-month prasugrel monotherapy followed by clopidogrel monotherapy
1-month DAPTDrug
1-month dual antiplatelet therapy comprising of aspirin and prasugrel followed by aspirin monotherapy
Primary outcomes
What the sponsor says the trial is designed to measure.
- Major bleedingTime frame: 1 month
- Cardiovascular composite endpointTime frame: 1 month
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Kyoto University Graduate School of Medicine
Kyoto, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.